MedTrace Logo

Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty

NCT02798835 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2020-09-04

Study results available
· View outcomes & findings →

Summary

This study investigates single injection adductor canal block (ACB) with or without intravenous dexamethasone and adductor canal catheter for pain management of total knee arthroplasty. This is a non-inferiority trial seeking to determine whether single injection ACB with dexamethasone is "no worse" than a continuous catheter.

Conditions

  • Total Knee Arthroplasty

Interventions

DRUG

Adductor canal block

Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.

DRUG

Adductor canal block with dexamethasone

Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.

DRUG

Adductor canal catheter

Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.

DRUG

Bupivacaine

Used in spinal anesthetic

DRUG

Fentanyl

May or may not be used in spinal anesthetic

DRUG

Ropivacaine 0.5% Injectable Solution

Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.

DRUG

Dexamethasone

To be given intravenously at time of nerve block to one of the study arms.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Steven Lee, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2016-12-31
Completion
2016-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02798835 on ClinicalTrials.gov